TY  - JOUR
PY  - 2007//
TI  - Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment
JO  - Annals of oncology
A1  - Bacci, G.
A1  - Balladelli, A.
A1  - Forni, C.
A1  - Ferrari, S.
A1  - Longhi, A.
A1  - Benassi, M. S.
A1  - Briccoli, A.
A1  - Serra, M.
A1  - Picci, P.
SP  - 2037
EP  - 2040
VL  - 18
IS  - 12
N2  - BACKGROUND: In 326 patients with Ewing's sarcoma family tumor (ESFT) and 628 extremity osteosarcoma (OS) treated with adjuvant and neo-adjuvant chemotherapy and event-free survivors 5 years from the beginning of treatment we evaluated outcome in the following years. Post 5-year follow-up for these patients was 9.7 years (5.5-29 years).  PATIENTS AND METHODS: Adverse events observed after 5-year follow-up were 73 (7.6%): 38 late relapses, nine leukemia, 14 second solid tumor, seven radioinduced sarcoma, three severe adriamycin-related cardiomyopathy, one suicide and one death by car crash.  RESULTS: Of the patients who developed late events, 16 (22.5%) are alive and event free after 8 years from the last treatment (2-22 years).  CONCLUSION: We conclude that the high rate of late adverse events after 5 years in patients with OS and ESFT is noteworthy and indicates that these patients should be followed for >5 years.<p /> <p>Language: en</p>
LA  - en
SN  - 0923-7534
UR  - http://dx.doi.org/10.1093/annonc/mdm382
ID  - ref1
ER  -